Pediatric Population Disease

Treatment with givinostat for ambulatory boys with Duchenne muscular dystrophy led to improved motion and reduced decline of muscle function and strength at 18 months, according to a poster at the 2024 MDA Clinical & Scientific Conference.

Risk for permanent disability in pediatric-onset MS decreased by 50% to 70% in an analysis of four diagnostic time points starting in 1993, likely due to improvements in treatment standards, according to results published in JAMA Neurology.